Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

68.13B

Market cap68.13B

Price-Earnings ratio

15.94

Price-Earnings ratio15.94

Dividend yield

0.56%

Dividend yield0.56%

Average volume

1.01M

Average volume1.01M

High today

$657.96

High today$657.96

Low today

$637.72

Low today$637.72

Open price

$657.96

Open price$657.96

Volume

714.21K

Volume714.21K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$532.60

52 Week low$532.60

Stock Snapshot

The current Regeneron(REGN) stock price is $649.86, with a market capitalization of 68.13B. The stock trades at a price-to-earnings (P/E) ratio of 15.94 and offers a dividend yield of 0.56%.

On 2026-07-06, Regeneron(REGN) stock moved within a range of $637.72 to $657.96. With shares now at $649.86, the stock is trading +1.9% above its intraday low and -1.2% below the session's peak.

Trading activity shows a volume of 714.21K, compared to an average daily volume of 1.01M.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $532.60.

REGN News

TipRanks 12h

Regeneron price target lowered to $800 from $990 at HSBC

HSBC lowered the firm’s price target on Regeneron (REGN) to $800 from $990 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted t...

Investing.com 14h

Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns - Investing.com

...

TipRanks 15h

Regeneron price target lowered to $750 from $785 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Regeneron (REGN) to $750 from $785 and keeps an Overweight rating on the shares. Large...

Analyst ratings

71%

of 31 ratings

Buy

71%

Hold

29%

Sell

More REGN News

Simply Wall St 2d

Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron Investors?

In June 2026, Regeneron Pharmaceuticals announced that the FDA and EMA accepted regulatory applications for cemdisiran to treat anti-acetylcholine receptor anti...

Simply Wall St 3d

Regeneron Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions

Regeneron Pharmaceuticals stock has delivered a 20.2% return over the past year, and with a high value score plus an undervalued read on market multiples, the c...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.